 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | STK-002 / Stoke Therap
Journal: Antisense Oligonucleotide STK-002 Increases OPA1 in Retina and Improves Mitochondrial Function in Autosomal Dominant Optic Atrophy Cells. (Pubmed Central) - Sep 12, 2024
STK-002 and enhanced OPA1 immunofluorescence were visualized in retinal ganglion cells of cynomolgus monkeys treated with the ASO. Cumulatively, these data support the progression of STK-002 toward the clinic as the first potential disease-modifying treatment for ADOA.